Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological characteristics and clinical outcomes  by Pezzano, S.C. et al.
Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological
characteristics and clinical outcomes
S. C. Pezzano1,*, C. Torres1,*, H. A. Fainboim2, M. B. Bouzas3, T. Schroder2, S. F. Giuliano3, S. Paz2, E. Alvarez4,
R. H. Campos1 and V. A. Mbayed1
1) Ca´tedra de Virologı´a, Facultad de Farmacia y Bioquı´mica, Universidad de Buenos Aires, 2) Unidad de Hepatopatı´as Infecciosas, Hospital F. J. Mun˜iz,
3) Unidad de Virologı´a, Hospital F. J. Mun˜iz, Ciudad Auto´noma de Buenos Aires and 4) Hospital Nacional Profesor Alejandro Posadas, Partido de Moro´n,
Provincia de Buenos Aires, Argentina
Abstract
Hepatitis B virus (HBV) is classiﬁed into eight major genotypes, A–H, which are geographically distributed worldwide. The aim of this
work was to describe the clinical characteristics associated with the HBV genotypes circulating in Buenos Aires city. The study included
139 patients infected with HBV, whose clinical courses were classiﬁed as acute symptomatic self-limiting hepatitis, inactive carrier state
and chronic active hepatitis (HBV e-antigen (HBeAg)-positive and HBeAg-negative). The HBV genotypes were determined in 128
patients by PCR–restriction fragment length polymorphism and phylogenetic analysis. Biochemical, virological, clinical and histological
features were analysed. A differential distribution of genotypes between acute symptomatic and chronic infections was found. Among
the acute cases, genotype F was predominant (65.2%, 30/46) and genotype D was rare (4.3%, 2/46), whereas among the chronic infec-
tions, a homogeneous distribution of genotypes A (26.8%, 22/82), D (31.7%, 26/82) and F (36.6%, 30/82), with an unusual presence of
genotypes B (1.2%, 1/82) and C (3.7%, 3/82), was observed. Regarding the liver histology of chronically infected patients, genotype F
tended to display higher histological activity indexes. Mutations related to HBV surface antigen immunoreactivity, antiviral resistance and
HBeAg-negative status were studied. This work constitutes, to our knowledge, the ﬁrst description of the clinical characteristics related
to HBV genotypes in Argentina, where the distribution of genotypes in patients with acute infection has not been reported previously.
Finally, it was established that genotype F is the prevalent genotype among the acute symptomatic infections in Buenos Aires city, and
that it shows a tendency to cause an adverse disease outcome among the chronic cases.
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Introduction
Hepatitis B virus (HBV) affects 350–400 million people
worldwide and accounts for one million deaths annually from
cirrhosis, liver failure and hepatocellular carcinoma [1,2].
The virus has been classiﬁed into eight major genotypes,
A–H, and has a worldwide geographical distribution [3].
Several studies have been carried out to investigate the clin-
ical relevance of the HBV genotypes with regard to antiviral
therapies [4,5] and, more controversially, to liver disease
severity [6,7].
In Argentina, the presence of genotypes A, D and F has
been previously reported [8,9]. However, there is no survey
of the clinical courses in relation to the different genotypes.
Thus, the aim of this work was to describe the clinical
characteristics associated with the HBV genotypes circulating
in Buenos Aires city.
Materials and Methods
Patients
This was a retrospective study (from July 1999 to March
2006) of adults, unrelated patients infected with HBV who
attend the F. J. Mun˜iz Hospital in Buenos Aires city. In
patients who underwent treatment, the sample analysed
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corresponded to the pretreatment period. Co-infections
with hepatitis C virus, human immunodeﬁciency virus or
hepatitis D virus were excluded.
Patients were divided into three groups. For the classiﬁca-
tion, previous reports [10,11] were taken into account.
Group 1 comprised 51 patients with acute symptomatic
self-limiting hepatitis (acute infections) with conﬁrmed
anti-HBV core antigen IgM and who had been HBV surface
antigen (HBsAg)-positive for less than 6 months from the
beginning of symptoms. The most common symptoms were
jaundice, loss of appetite, nausea, and pain in the right
upper part of the abdomen. The presence of anti-HBsAg anti-
bodies was conﬁrmed; however, 12 patients interrupted their
follow-up after the HBsAg and viral load became undetectable.
Group 2 comprised 21 patients deﬁned as inactive carri-
ers, who had been HBsAg–positive for at least 6 months,
were HBV e-antigen (HBeAg)-negative (HBeAg–, had viral
loads under 104 copies/mL, and had persistently normal ala-
nine aminotransferase (ALT) levels.
Group 3 comprised 67 patients with chronic active infec-
tions (chronic hepatitis), who had been HBsAg-positive for at
least 6 months, had viral loads above 104 copies/mL, had ele-
vated ALT, had ﬁbrosis (F) scores >2, and had histological activ-
ity index (HAI) scores >3. This group was further subdivided
into HBeAg-positive (HBeAg+) (n = 32) and HBeAg– (n = 35).
The study was carried out according to the World Medi-
cal Association Declaration of Helsinki and was approved by
the Ethical Committee of the School of Pharmacy and Bio-
chemistry, University of Buenos Aires.
Laboratory testing and evaluation of liver biopsy
HBV serological markers were analysed with the Axsym
Abbott system (MEIA) (HBsAg v2.0, HBeAg and IgM anti-
core; Abbott Diagnostics, Wiesbaden, Germany), HBV DNA
in serum was quantiﬁed by using the Amplicor HBV Monitor
Test v1.0 (Roche Diagnostics, Meylan, France), and ALT lev-
els were expressed as multiples of the upper limit of the
normal value (41 UI/L).
Liver biopsy specimens were evaluated according to the
modiﬁed Knodell score, and categorized as mild or advanced
ﬁbrosis (F £2 or F >2, respectively) and as low or high necr-
oinﬂammation (HAI £3 or HAI >3, respectively). HAI ‡7 was
considered to be a histological indication for treatment. All
patients gave informed consent to undergo liver biopsy.
HBV genotyping
Genotyping of the samples by nested PCR–restriction fragment
length polymorphism on the S gene was based on that reported
by Zeng et al. [12], modiﬁed to improve the detection of
genotype F.
Brieﬂy, DNA was extracted from a 200-lL serum sample
by using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden,
Germany). The PCR was perfomed with primers 5¢-
CTGCTGGTGGCTCCAGTTC-3¢ (nucleotides 57–75) and
5¢-AGAAAATTGGTAACAGMGGYA-3¢ (nucleotides 815–
795) in the ﬁrst round, and 5¢-GCGGKGTKTTTCTTGTTG
ACAA-3¢ (nucleotides 203–224) and 5¢-GGGACTCAAGAT-
GYTGYACAG-3¢ (nucleotides 787–767) in the second
round, with the following conditions: 4 min at 95C, 35
cycles of 1 min at 95C, 45 s at 57C (ﬁrst round) or 45 s
at 60C (second round) and 1 min at 72C, with a ﬁnal
extension of 10 min at 72C. The ampliﬁed product spanned
585 nucleotides. The restriction of the PCR product was
performed with the enzymes EaeI, MspI, StyI, MboI and BsrI.
Ampliﬁcation of the basal core promoter/precore gene
(BCP-pC) regions
Primers 5¢-ATGGAGACCACCGTGAACGC-3¢ (nucleo-
tides 1608–1627) and 5¢-CCCACCTTATGAGTCCAAGG-3¢
(nucleotides 2484–2465) and primers 5¢-TGCCAACAGTCT
TACATAAGMG-3¢ (nucleotides 1639–1660) and 5¢-GAGTT
CTTCTTCTAGGGGACCTG-3¢ (nucleotides 2381–2359) were
used in the ﬁrst and second rounds, respectively, of a nested
PCR to amplify the BCP-pC of the chronic samples. The
reaction conditions in both rounds were: 5 min at 94C, 35
cycles of 30 s at 94C, 30 s at 53C and 45 s at 72C, and a
ﬁnal extension of 10 min at 72C. The ampliﬁed product
spanned 742 nucleotides.
Sequencing and phylogenetic analysis
The samples were sequenced in an ABI3130XL sequencer
(Applied Biosystems, Carlsbad, California, USA). Sequences
were aligned with ClustalX v1.83 [13], and edited with Bio-
edit v7.0.9.0 software [14]. Phylogenetic analyses were per-
formed using the maximum-likelihood method with tree
bisection and reconnection branch swapping (PAUP* v4.0b10
[15]). The model of nucleotide substitution estimated by the
Modeltest 3.7 program [16] was GTR+I+c. The robustness
of the phylogenetic grouping was evaluated by a neighbor-
joining bootstrap analysis with 10 000 replicates (PAUP*
v.4.0b10).
Statistical analysis
Quantitative variables were analysed by non-parametric tests
(Mann–Whitney), and categorical variables by chi-squared or
Fisher’s exact tests. The data were stratiﬁed into 2 · 2
tables, and measures of association were tested. The
strength of the relationship was estimated by using ORs with
95% CIs. Multivariate analyses with logistic regression were
used to determine the independent factors associated with
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FIG. 1. Maximum-likelihood phylogenetic tree constructed on the small S gene sequences (525 bp) of genotypes from Buenos Aires city and
several countries from all over the world. The numbers at each node correspond to neighbor-joining bootstrap values (10 000 replicates).
Reference sequences for genotypes/subgenotypes are indicated. Genotype E was used as the outgroup. HBeAg, hepatitis B e-antigen.
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FIG. 2. Maximum-likelihood phylogenetic tree constructed on the small S gene sequences (525 bp) of genotype D from Buenos Aires city (BA)
and several countries from all over the world. The numbers at each node correspond to neighbour-joining bootstrap values (10 000 replicates).
The sequences reported in this work are shown in bold. Sequences from other genotypes were also represented. Genotypes A and B were used
as outgroups.
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the clinical course and the HBeAg status of the infection.
Dummy variables were created for the variable ‘genotype’
(with more than two classes). The Spearman correlation test
was used to evaluate the related variables. Differences were
considered to be signiﬁcant for p-values <0.05. Statistical
analyses were performed using STATA 9.1 software [17].
Results
Samples were genotyped by nested PCR–restriction fragment
length polymorphism (n = 128) and validated by phylogenetic
analysis (n = 121). Eleven PCR-negative samples were
excluded from further analysis. Genotyping discrepancies
between the methodologies were found in nine of the 121
sequenced samples (7.4%).
The distribution of genotype F sequences in the phyloge-
netic tree showed that a unique source of viruses was not
supported, either for acute or for chronic isolates (Fig. 1).
The analysis of the diversity of genotype D isolates showed
that phylogeographical relationships of Argentinean samples
were not evident, dismissing the existence of a local cluster
(Fig. 2).
Comparative epidemiological, biochemical, virological, clini-
cal and histological features of the studied population are
shown in Tables 1 and 2.
The overall prevalence of HBV genotypes in the 128 cases
analysed was as follows: genotype F, 46.9% (60/128); geno-
type A, 28.1% (36/128); genotype D, 21.9% (28/128); geno-
type C, 2.3% (3/128); and genotype B, 0.8% (1/128).
A differential distribution of genotypes with regard to the
clinical course of infection was found. Among the 46 acute
infections, the distribution was as follows: genotype F, 65.2%
(30/46); genotype A, 30.4% (14/46); and genotype D, 4.3%
(2/46). However, among the 82 chronically infected patients,
a homogeneous distribution of genotypes A, D and F was
observed (26.8% (22/82), 31.7% (26/82) and 36.6% (30/82),
respectively), as well as a few cases of genotypes B (1.2%, 1/
82) and C (3.7%, 3/82). Univariate statistical analysis showed
that genotype F was signiﬁcantly more common among acute
infections than among the total number of chronic cases; in
contrast, genotype D was barely present in this group
(Table 1). For a multivariate analysis, genotype, gender and
age were considered as variables. The only one that indepen-
dently associated with the course of infection was genotype.
Genotypes F and A were about 13-fold and eight-fold more
TABLE 1. Epidemiological features of the studied population and hepatitis B virus (HBV) genotype distribution
Characteristic Total patients Acute infections
Chronic
infections
Patients with chronic hepatitis
Inactive carriersHBeAg+ HBeAg)
Total 139 51 88 32 35 21
Not detectable by PCR 11 5 6 0 3 3
Genotypedd,f,k 128 46 82 32 32 18
A 36 14 22 10 8 4
B 1 0 1 1 0 0
C 3 0 3 2 1 0
Db,e,g 28 2 26 4 14 8
Fc 60 30 30 15 9 6
Gender (men/women) 88 : 40 33 : 13 55 : 27 23 : 9 19 : 13 13 : 5
Age (years), median (range),hk 39 (18–79) 36.5 (18.0–78.0) 41 (20–79) 36 (20–79) 44 (20–65) 38 (22–58)
ALT (· normal value),
median (range), ni
2.4 (1.0–166.9), 119 25.5 (1.2–166.9), 38 1.4 (1.0–10.2), 81 2.8 (1.0–10.2), 31 1.20 (1.00–6.76), 32 1.00
Viral load (log10 copies/mL),
median (range), nj,k
5.6 (3.0–7.6),79 7.6 (5.3–7.6),32 4.7 (3.0–7.6),29 3.0 (3.0–3.8),18
Fibrosis, n F £2/F > 2 51 : 29 13 : 19 21 : 10 17 : 0
HAI, n HAI £3/HAI >3, HAI ‡7a 28 : 50, 14 5 : 26, 10 6 : 24, 4 17 : 0, 0
ALT, alanine aminotransferase; n, number of patients; F, liver ﬁbrosis score; HAI, liver histological activity index; HBeAg, hepatitis B e-antigen. ALT normal value: 41 UI/L.
aNumber of patients with HAI ‡7, which is considered to be the histological indication for treatment.
Course of infection:
bGenotype D acute vs. chronic, OR 0.10, 95% CI 0.01–0.43, p 0.0003.
cGenotype F acute vs. chronic, OR 0.31, 95% CI 0.13–0.70, p 0.0018.
dAcute vs. chronic, ORgenotype F 13.00, 95% CI 2.83–59.72, p 0.0010; ORgenotype A 8.27, 95% CI 1.69–40.43, p 0.0091; adjusted by genotype with reference to genotype D.
HBeAg status:
eGenotype D chronic HBeAg+ vs. genotype D chronic HBeAg) inactive carriers (ICs) included, OR 0.18, 95% CI 0.04–0.64, p 0.0028.
fChronic HBeAg+ vs. chronic HBeAg) ICs included, ORgenotype F 5.56, 95% CI 1.52–20.00, p 0.0092; ORgenotype A 4.55, 95% CI 1.18–16.67, p 0.0278; adjusted by genotype
with reference to genotype D.
gGenotype D chronic HBeAg+ vs. genotype D chronic HBeAg) ICs not included, OR 0.18, 95% CI 0.04–0.73, p 0.0054.
hAge: chronic HBeAg+ vs. chronic HBeAg) ICs not included, p 0.0089.
iALT: chronic HBeAg+ vs. chronic HBeAg) ICs not included, p 0.0002.
jViral load: chronic HBeAg+ vs. chronic HBeAg) ICs not included, p <0.0001.
kChronic HBeAg+ vs. chronic HBeAg) ICs not included, ORgenotype F 11.11, 95% CI 1.06–100.00, p 0.0444; with reference to genotype D. ORAge 0.92, 95% CI 0.85–0.99,
p 0.0214; ORviral load 6.67, 95% CI = 2.3320.00, p 0.0003; adjusted by genotype, age and viral load.
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associated with the acute course of infection than geno-
type D (Table 1).
For the analysis of factors associated with HBeAg status, a
multivariate model including the inactive cases in the HBeAg–
group was built, with genotype, gender and age as variables.
As a result, only genotype remained independently associated
with HBeAg status, genotypes F and A being about ﬁve-fold
more associated with HBeAg+ status than genotype D
(Table 1).
Additionally, in a further analysis, we included other viro-
logical and clinical variables such as viral load, liver ﬁbrosis and
HAI. As these variables partly deﬁne the chronic inactive car-
riers, these patients were excluded. Also, the ALT level was
not considered in the analysis, because it showed a correla-
tion with viral load (r = 0.63, 95% CI 0.44–0.77, p <0.0001).
Then, high viral load levels and young ages associated with
HBeAg+ status, and genotype F was about 11-fold more asso-
ciated with HBeAg+ status than genotype D (Table 1).
Even though genotype distribution in relation to liver his-
tology was not statistically signiﬁcant, it was noteworthy that
91% of the chronic hepatitis cases caused by genotype F pre-
sented high necroinﬂammatory activity (HAI >3, 20/22). In
addition, genotype F was responsible for seven of 14 cases
that reached HAI ‡7, and was found in two of the four cases
of cirrhosis detected (Table 2).
Mutations in three different genetic regions (ORF-S, ORF-
P and BCP-pC) were studied (Table 3).
Analysis of the amino acid substitutions within the major
hydrophilic region of HBsAg was performed by genotype.
For genotype A, only three of the seven mutations found
were previously recognized as affecting the immunoreactivity
of HBsAg. For genotype D, six of 20 mutations were previ-
ously described, and for genotype F, most of the mutations
detected were previously characterized.
In addition, three patients displayed antiviral resistance
mutations in the polymerase gene.
We also investigated the presence of mutations associated
with the HBeAg seroconversion. Despite the fact that most of
the mutations were found among the HBeAg– cases, three
HBeAg+ patients presented the A1762T/G1764A mutations.
TABLE 2. Biochemical, virological, clinical and histological features of the hepatitis B virus (HBV) chronic infections
Characteristic Total patients Acute infection Total chronic






A 25 : 11 8 : 6 17 : 5 8 : 2 5 : 3 4 : 0
D 17 : 11 0 : 2 17 : 9 1 : 3 10 : 4 6 : 2
F 43 : 17 25 : 5 18 : 12 11 : 4 4 : 5 3 : 3
Age (years), median (range), nc–e
A 41.5 (36.0–78.0), 36 42.5 (24–78), 14 40.5 (21.0–59.0), 22 42.5 (21.0–58.0), 10 42 (24–59), 8 37.5 (34.0–52.0), 4
D 43.0 (20.0–65.0), 28 27.5 (27–28), 2 45 (20–65), 26 29.5 (20.0–52.0), 4 45 (32–65), 14 49.5 (29.0–52.0), 8
F 36.0 (18.0–79.0), 60 33.5(18–59), 30 38.5 (20.0–79.0), 30 33 (20–79), 15 47 (27–62), 9 36 (25–58), 6
ALT (· normal value), median (range), nf,g
A 25 (3–90), 11 1.2 (1.0–7.7), 21 4.0 (1.4–7.7), 9 1.0 (1.0–1.4), 8 1.00, 4
D 4.45 (3.90–5.00), 2 1.2 (1.0–6.8), 26 3.3 (1.2–6.0), 4 1.7 (1.0–6.8), 14 1.00, 8
F 33 (1.2–166.9), 25 1.6 (1.0–10.2), 30 2.3 (1.2–10.2), 15 1.0 (1.0–5.5), 9 1.00, 6
Viral load (log10 copies/mL), median (range), n
h–j
A 5.3 (3.0–7.6), 21 7.6 (5.3–7.6), 10 4.2 (3.0–6.5), 7 3.25 (3.0–3.5), 4
D 4.7 (3.0–7.6), 25 7.6 (7.0–7.6), 4 5.2 (3.0–7.6), 13 3.0 (3.0–3.8), 8
F 6.4 (3.0–7.6), 29 7.6 (6.0–7.6), 15 4.6 (3.0–7.6), 8 3.0 (3.0–3.1), 6
Fibrosis, n F £2/F >2
A 11 : 10 3 : 7 4 : 3 4 : 0
D 20 : 5 3 : 1 10 : 4b 7 : 0
F 18 : 12 6 : 9 6 : 3b 6 : 0
HAI, n HAI £ 3/HAI > 3, HAI ‡7a
A 9 : 12, 4 1 : 9, 4 4 : 3, 0 4 : 0
D 11 : 14, 3 2 : 2, 1 2 : 12, 2 7 : 0
F 8 : 20, 7 2 : 12, 5 0 : 8, 2 6 : 0
ALT, alanine aminotransferase; n, number of patients; F, liver ﬁbrosis score; HAI, liver histological activity index; HBeag, hepatitis B e-antigen. ALT normal value: 41 UI/L.
aNumber of patients with HAI ‡7, which is considered to be the histological indication for treatment.
bCirrhosis cases: two genotype F, HBeAg); two genotype D, HBeAg).
Age:
cGenotype A vs. genotype F, p 0.029.
dGenotype D vs. genotype F, p 0.0365.
eGenotype A acute vs. genotype F acute, p 0.0452.
ALT:
fGenotype A chronic HBeAg + vs. genotype A chronic HBeAg), p <0.0001.
gGenotype A chronic HBeAg) vs. genotype D chronic HBeAg), p 0.00620.
Viral load:
hGenotype A chronic HBeAg+ vs. genotype A chronic HBeAg), p 0.0002.
iGenotype D chronic HBeAg+ vs. genotype D chronic HBeAg), p 0.0127.
jGenotype F chronic HBeAg+ vs. genotype F chronic HBeAg), p 0.0107.
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For genotype A, the most common mutations were A1762T/
G1764A, whereas G1896A was not found. In contrast, for
genotypes F and D, G1896A was the most abundant mutation,
followed by A1762T/G1764A and G1899A. It is important to
note that all of the genotype F and D sequences had a T in
position 1858, whereas all of the genotype A samples had a C.
Discussion
The distribution of genotypes described in this survey is a
reﬂection of the demographic history of our region. The high
prevalence of genotype F is in agreement with previous
reports [8,18] and might be related to its autochthonous ori-
gin, as it was predominantly found among the original People
of America [19–21]. The circulation of genotypes A and D is
explained by the presence of Europeans who have migrated
to Argentina since the colonization period [9,22]. It was
noteworthy to ﬁnd genotypes B and C, which were isolated
from patients from Asian countries. The presence of an
Asian population in Argentina is related to a more recent
immigration process that occurred since 1960 with incre-
ments during the 80s and 90s.
When the distribution of genotypes was analysed with
respect to the different clinical courses, we found that geno-
types F and A were more associated with acute infections
than genotype D, whereas genotype D was associated with
chronic infections.
In order to explain these results, several proposals are
discussed.
In the ﬁrst place, the differences found between acute and
chronic infections are not attributable to different risk fac-
tors. Although the transmission modes were unknown in
many cases, sexual contact was suspected as the main route
of infection, and intravenous drug use was excluded in most
patients.
TABLE 3. Nucleotide or amino acid substitutions on the S, P and basal core promoter/precore gene (BCP-pC) open reading
frames (ORFs)





isolates Description Sequences analysed Mutation
No. of isolates
(HBeAg+/))
A (n = 32) T116N 1 a rtS202I 1 d A (n = 14) A1762T 4 (1/3)
M133T 1 b HBeAg+/): 7/7 G1764A 3 (1/2)
T143S 1 b* A1814C 1 (0/1)
Y161F 1 T1815C 1 (0/1)
E164G 1 ** G1816T 1 (0/1)
S174T 1 G1816A 1 (0/1)
V177A 1 G1899A 1 (0/1)
del (21 nt) 2 (0/2)
B (n = 1) T126A 1 a, c
C (n = 3)
D (n = 27) T/V118A 2 c rtL180M 1 e D (n = 19) A1762T 9 (1/8)
R122Q 2 b* rtS202C 1 e HBeAg+/): 4/15 G1764A 7 (1/6)
T125M 9 rtM204V 1 e G1816T 1 (0/1)
P/T127A 2 C1817T 1 (0/1)
G130N 1 c, b A1838G 1 (0/1)
S143L 1 b G1896A 11 (0/11)
G159A 2 G1899A 6 (0/6)
S174N 2 ins T1848 1 (0/1)
L175S 1
F (n = 58) T114S 1 b* rtL180M 1 f F (n = 23) A1762T 6 (1/5)
S117I 1 rtM204V 1 f HBeAg+/): 11/12 A1762T 6 (1/5)
L127V 1 A1814C 1 (0/1)
Q129L 1 a*, b*, c* A1819T 2 (0/2)
S140T 10 c G1896A 8 (0/8)
G145A 1 a G1899A 3 (0/3)
Q178P 1 ins G1774 2 (1/1)
del T1847 1 (0/1)
aa, amino acidic position on small S gene; HBeAg, hepatitis B virus e-antigen; nt, nucleotides; rt, amino acidic position on the retrotranscriptase domain of the polymerase
gene.
Mutations associated with: avaccine escape, bfailure in diagnostic assays, and cimmunotherapy escape [27].
*The position has been described but not the speciﬁc mutation. **The position has been described as reducing hepatitis B virus surface antigen reactivity without further
description.
dResistance to entecavir in combination with L180M/M204V mutations.
eOne patient presented the triple mutation pattern that confers resistance to lamivudine, telbivudine and entecavir.
fOne patient presented the mutation pattern that confers resistance to lamivudine and telbivudine. The only patient under antiviral treatment (infected with genotype F and
presenting the resistance pattern rtL180M/rtS202G/rtM204V) was excluded from this analysis.
Nucleotide accession numbers: S gene: DQ776245–48, DQ776267–74, EU304330–33, EU366114–41, FJ657518–29, GU207480–93, Hm154937–89, Hm164132–33.
BCP-pC gene: Hm164134, Hm214718–58, Hm216293, Hm216296, Hm216308–10, Hm216318, Hm216333, Hm216335–38, Hm216341, Hm216347–48.
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Additionally, a common source of acute infections by
genotype F was dismissed. First, samples were taken from
epidemiologically unrelated individuals. Second, samples were
dated over a 4-year period (2001–2005), and most of them
were distant from each other. Among the samples separated
by less than 6 months, we found that many of them belonged
to different subgenotypes, dismissing the existence of a com-
mon source. However, for those samples belonging to the
same subgenotype, a common origin could not be rejected
or conﬁrmed. Finally, neither acute nor chronic infections
grouped as separated clusters in the phylogenetic tree.
Another argument to explain the different distribution of
genotypes between acute and chronic cases is that if the
infections by genotype D were preferentially asymptomatic,
they would be under-represented among the acute cases
reported here. However, infections with genotype D have
been described as acute symptomatic in other countries
[23,24]. Furthermore, the existence of local variants with
particular characteristics and behaviours was dismissed at
least by the phylogenetic analysis of the Argentinean geno-
type D isolates, which were intermingled with sequences
from all around the world.
With regard to the predominance of genotype F among
the acute infections, we consider that this could not only
be the result of the prevalence of genotype F in the gen-
eral population, but also could be determined by its pres-
ence in the highly contagious HBeAg+ chronic group. In
line with this, genotype D was found to be associated with
HBeAg– status, and was hardly found in the acute infec-
tions. These observations might suggest a temporal varia-
tion in the distribution of genotypes, whereby acute
infections could be an expression of the genotypes cur-
rently being transmitted to new hosts (mainly from the
chronic HBeAg+ hosts).
Another point to be argued is the high prevalence of
genotype F that we found among chronic HBeAg+ infections,
as another group has found it to be associated with HBeAg–
status [8]. However, the differences between the populations
analysed suggest that the earlier medical assistance received
by the patients analysed here allows the detection of HBV
infections in early stages, even before the HBeAg serocon-
version event.
The molecular bases for HBeAg seroconversion involve
different characterized mutations. Whereas, for genotype A,
the A1762T/G1764A mutations were mainly found, for geno-
types F and D the G1896A mutation was most common. It
is noteworthy that, in spite of genotypes F and D having the
ability to seroconvert by the G1896A change (that is, they
display a T at position 1858 opposite to position 1896 in the
stem loop of the encapsidation signal), both genotypes were
not equally distributed among the HBeAg– infections. This
suggests different behaviours regarding the seroconversion
process.
Other analysed mutations involve the MHR of HBsAg.
These variants have been reported for their clinical
importance, and their prevalence could be about 6–12% [25]
(in our survey, the prevalence was 14.9%). Even though the
patients were not previously vaccinated, three of them dis-
played vaccine escape mutations, indicating that these vari-
ants are currently circulating in the population. It is
interesting to note that the S140T mutation, related to
immunotherapy escape, has been frequently found in geno-
type F (although patients were not treated) and mainly in the
acute infections.
Amino acid substitutions in the polymerase gene related
to antiviral resistance were scarce, as expected, because the
analysed samples are from the pretreatment stage.
Despite the fact that genotype distribution in relation to
liver histology did not have statistical support, we found
that genotype F displayed higher HAIs among the chronic
patients. These ﬁndings might suggest a more adverse out-
come for genotype F in chronic infection. Although fewer
studies have analysed the clinical characteristics related to
genotype F, their ﬁndings are in line with our results
[20,26].
In conclusion, this work presents, to our knowledge, the
ﬁrst description of the clinical characteristics related to HBV
genotypes in Argentina. Furthermore, the distribution of
HBV genotypes in patients with acute infection has not been
previously reported in our region. According to this, it was
established that genotype F is the prevalent genotype among
the acute symptomatic infections in Buenos Aires city, and
that it shows a tendency to cause an adverse disease out-
come among the chronic cases.
Finally, more and different approaches are needed to con-
tinue unravelling the behaviour of HBV genotypes, particu-
larly the genotype F prevalent in Argentina.
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